Published in Clin Cancer Res on January 07, 2014
Personalized Treatment Selection for Metastatic Breast Cancer | NCT00780676
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst (2015) 2.13
Full antagonism of the estrogen receptor without a prototypical ligand side chain. Nat Chem Biol (2016) 2.05
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol (2016) 1.83
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. Clin Cancer Res (2015) 1.64
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med (2015) 1.52
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clin Cancer Res (2015) 1.29
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol (2015) 1.22
Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol (2015) 1.22
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep (2014) 1.21
Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. Genome Biol (2014) 1.19
ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clin Cancer Res (2015) 1.18
Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. Breast Cancer Res (2015) 1.08
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife (2016) 1.06
Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget (2015) 1.01
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun (2016) 0.99
Endocrine resistance in breast cancer - An overview and update. Mol Cell Endocrinol (2015) 0.93
Targeted therapies for ER+/HER2- metastatic breast cancer. BMC Med (2015) 0.91
Estrogen receptor mutations in breast cancer--new focus on an old target. Clin Cancer Res (2014) 0.87
Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer (2017) 0.87
Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Res (2014) 0.86
Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. Oncotarget (2016) 0.83
MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proc Natl Acad Sci U S A (2014) 0.82
Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. J Natl Cancer Inst (2014) 0.82
Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer. J Med Chem (2015) 0.82
Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. Onco Targets Ther (2015) 0.82
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol (2015) 0.81
The changing role of ER in endocrine resistance. Breast (2015) 0.80
Revealing the Complexity of Breast Cancer by Next Generation Sequencing. Cancers (Basel) (2015) 0.80
Tamoxifen Resistance: Emerging Molecular Targets. Int J Mol Sci (2016) 0.80
Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. Endocr Relat Cancer (2015) 0.80
Activating ESR1 Mutations Differentially Impact the Efficacy of ER Antagonists. Cancer Discov (2016) 0.80
The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Mol Cell Endocrinol (2015) 0.80
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A (2016) 0.78
Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers. Front Oncol (2015) 0.78
Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance. PLoS One (2016) 0.78
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst (2014) 0.78
Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations. Steroids (2014) 0.78
Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer. Cell Rep (2017) 0.77
Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. Oncologist (2015) 0.77
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist (2016) 0.77
Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol (2015) 0.77
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Oncotarget (2016) 0.77
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene (2016) 0.76
Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res (2016) 0.76
Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. Eur J Nucl Med Mol Imaging (2015) 0.76
Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing. Oncotarget (2015) 0.76
Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget (2017) 0.76
The potential for liquid biopsies in the precision medical treatment of breast cancer. Cancer Biol Med (2016) 0.76
Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate. World J Clin Oncol (2016) 0.76
ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat (2016) 0.75
New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and other Targeted Therapies. Clin Cancer Res (2016) 0.75
Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. Front Oncol (2017) 0.75
Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer. Mol Oncol (2016) 0.75
Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res (2016) 0.75
Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI. Sci Rep (2016) 0.75
Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol (2017) 0.75
Antiestrogens: structure-activity relationships and use in breast cancer treatment. J Mol Endocrinol (2016) 0.75
Exome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers. PLoS One (2015) 0.75
Are Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer? Iran J Cancer Prev (2016) 0.75
The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus. Transl Oncogenomics (2016) 0.75
COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR. Nat Commun (2016) 0.75
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife (2016) 0.75
Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. Breast Cancer Res Treat (2016) 0.75
How drug resistance takes shape. Elife (2016) 0.75
Role of steroid receptor and coregulator mutations in hormone-dependent cancers. J Clin Invest (2017) 0.75
Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy. Springerplus (2015) 0.75
Targeted therapy in cancer. Cancer Chemother Pharmacol (2015) 0.75
Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. Oncotarget (2016) 0.75
Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients. Transl Oncol (2017) 0.75
Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers. Elife (2017) 0.75
A Review of Fulvestrant in Breast Cancer. Oncol Ther (2017) 0.75
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife (2017) 0.75
Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors. Cancer Res (2017) 0.75
Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells. Clin Cancer Res (2017) 0.75
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. Curr Breast Cancer Rep (2017) 0.75
Liquid biopsy: unlocking the potentials of cell-free DNA. Virchows Arch (2017) 0.75
Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients. Oncotarget (2017) 0.75
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
Mechanisms of endocrine resistance in breast cancer. Annu Rev Med (2011) 4.32
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet (2013) 4.03
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol (2000) 4.03
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol (2010) 3.88
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
How to apply de Bruijn graphs to genome assembly. Nat Biotechnol (2011) 3.36
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol (2000) 3.33
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26
A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol (2010) 2.72
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry (1997) 2.32
Estrogen receptor mutations in human disease. Endocr Rev (2004) 2.08
D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res (2013) 2.05
Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol (1996) 1.99
An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res (1997) 1.82
Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J Natl Cancer Inst (1995) 1.64
Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci (2012) 1.44
ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet (2008) 1.33
Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes. Mol Endocrinol (1997) 1.22
Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res (1994) 1.17
Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine. EMBO J (1997) 1.13
Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer (2008) 1.05
Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci (2009) 1.04
Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem (2002) 1.03
The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat (1994) 0.98
Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat (1994) 0.96
Absence of ESR1 amplification in a series of breast cancers. Int J Cancer (2008) 0.92